Skip to main content

Progressive Multifocal Leukoencephalopathy

2
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
CE-VST01-JCPhase 21 trial
Active Trials
NCT05541549Unknown60Est. Apr 2025
NeoImmuneTech
NeoImmuneTechMD - Rockville
1 program
1
NT-I7Phase 11 trial
Active Trials
NCT04781309Completed12Est. Nov 2025
Biogen
BiogenCAMBRIDGE, MA
4 programs
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal LeukoencephalopathyN/A1 trial
JC Virus Reactivation in Multiple SclerosisN/A1 trial
TysabriN/A1 trial
mefloquinePHASE_1_21 trial
Active Trials
NCT01211639Terminated24Est. Aug 2014
NCT02004444Completed50Est. Jan 2016
NCT03399981Completed80,327Est. Dec 2023
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpCE-VST01-JC
Biogenmefloquine
NeoImmuneTechNT-I7
BiogenTysabri
BiogenGenetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
BiogenJC Virus Reactivation in Multiple Sclerosis

Clinical Trials (6)

Total enrollment: 80,510 patients across 6 trials

A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML

Start: Feb 2023Est. completion: Apr 202560 patients
Phase 2Unknown

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Start: Jan 2009Est. completion: Nov 201037 patients
Phase 1/2Terminated

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Start: May 2021Est. completion: Nov 202512 patients
Phase 1Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Start: Jun 2017Est. completion: Dec 202380,327 patients
N/ACompleted
NCT01211639BiogenGenetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Start: Oct 2010Est. completion: Aug 201424 patients
N/ATerminated
NCT02004444BiogenJC Virus Reactivation in Multiple Sclerosis

JC Virus Reactivation in Multiple Sclerosis

Start: Oct 2010Est. completion: Jan 201650 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.